Table 2.

Summary of Predictors of mortality in HIV-associated TB patients in Serowe/Palapye district Botswana 2013

Variables	Hazard ratio (95% CI)	P	Adjusted HR (95% CI)	P
Age group, year
< 35	1	–	–	–
35–59	0.89 (0.46–1.7)	0.722	1.5 (0.75–3)	0.245
≥ 60	3.15 (1.28–7.73)	0.012	4.8 (1.8–13)	0.002
Male sex	1.22 (0.67–2.23)	0.513	–	–
Unemployed	1.2 (0.59–2.42)	0.627	–	–
Smoker	2.53 (0.76–8.42)	0.130	0.66 (0.13–3.4)	0.619
Body weight < 50 kg	2.1 (0.94–4.71)	0.072	1.8 (0.7–4.5)	0.205
Smear positive PTB	0.5 (0.27–0.93)	0.028	–	–
Extrapulmonary	1.12 (0.59–2.13)	0.739	–	–
Previous TB	0.74 (0.27–2.01)	0.571	–	–
Fever	1.58 (0.85–2.94)	0.153	–	–
Productive cough	0.94 (0.46–1.92)	0.870	–	–
Night sweats	0.55 (0.26–1.16)	0.116	–	–
Loss of weight	2.33 (1.07–5.04)	0.032	–	–
Duration of symptoms > 3 months	3.85 (0.47–31)	0.207	–	–
No ART use during TB treatment	2.49 (1.31–4.73)	0.005	5.6 (2.9–11)	< 0.001
ART naïve	1.2 (0.66–2.2)	0.569	–	–
OI other than TB	7.76 (3.96–15.25)	< 0.001	8.5 (4–18.4)	< 0.001
CD4 counts cells/μl at TB < 200	2.02 (1.01–4.04)	0.046	–	–
Hemoglobin < 10 g/dl	2.4 (1.3–4.5)	0.007	2.44 (1.3–4.6)	0.029
Major Side effect	4.84 (2–12.3)	0.001	5 (1.6–17)	0.007
IRIS	1.1 (0.53–2.27)	0.808	–	–
Diabetes mellitus	0.049 (0–2559)	0.586	–	–

TB tuberculosis, ART antiretroviral therapy, IRIS immune reconstitution inflammatory syndrome, HR hazard ratio, CI Confidence Interval. Major side effect found were Hepatoxicity (8/9), and Stevens Johnson syndrome 1/9 OI: opportunistic infection, and ART use during TB treatment: time-updated variables